481 related articles for article (PubMed ID: 28653616)
1. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis.
Liu CL; Lee HC; Chen CC; Cho DY
Clin Invest Med; 2017 Jun; 40(3):E146-E157. PubMed ID: 28653616
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis.
Yuan F; Peng W; Yang C; Zheng J
Int J Surg; 2019 Jun; 66():1-11. PubMed ID: 30890377
[TBL] [Abstract][Full Text] [Related]
3. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
4. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
[TBL] [Abstract][Full Text] [Related]
6. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
7. Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.
Fan G; Zhao Q; Lu P; Chen H; Tan W; Guo W; Liu C; Liu J
Medicine (Baltimore); 2020 Apr; 99(15):e18964. PubMed ID: 32282692
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
[TBL] [Abstract][Full Text] [Related]
9. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
11. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
12. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
Chen L; Wang G; Zheng F; Zhao H; Li H
Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.
Yuan C; Liang Y; Zhu K; Xie W
J Orthop Surg Res; 2023 Jun; 18(1):447. PubMed ID: 37349750
[TBL] [Abstract][Full Text] [Related]
16. Four-Year Teriparatide Followed by Denosumab
Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials.
Lou S; Lv H; Li Z; Zhang L; Tang P
BMJ Open; 2018 Mar; 8(3):e015187. PubMed ID: 29500198
[TBL] [Abstract][Full Text] [Related]
18. [Once-weekly teriparatide treatment on osteoporosis].
Nakano T
Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS; Chang AB
Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
